文献速递临床试验与 GCP

斯堪的纳维亚无并发症主动脉夹层治疗试验:一项随机对照试验的研究方案

Scandinavian trial of uncomplicated aortic dissection therapy: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-03-23

该试验为在丹麦、挪威、瑞典、芬兰和冰岛23个中心开展的随机、开放标签、优效性临床试验,纳入年龄≥18岁、无并发症B型主动脉夹层病程<4周的患者,随机接受标准药物治疗(SMT)或SMT+TEVAR(TEVAR须在症状发作后2-12周内进行),主要评估早期TEVAR能否改善5年生存率,并评估费用和生活质量影响。

要点

  • 纳入年龄≥18岁、无并发症B型主动脉夹层病程<4周的患者。
  • 随机分SMT组或SMT+TEVAR组,TEVAR须在症状发作后2-12周内进行。
  • 主要问题是早期TEVAR能否改善无并发症B型主动脉夹层患者5年生存率。

核心结论

  • 该试验将评估早期TEVAR能否改善无并发症B型主动脉夹层患者5年生存率。
  • 费用和生活质量影响数据将为治疗策略决策提供急需的其他因素信息。

研究设计与样本

  • 随机、开放标签、优效性临床试验,平行分组,在丹麦、挪威、瑞典、芬兰和冰岛23个临床中心开展。
  • 纳入年龄≥18岁、无并发症B型主动脉夹层病程<4周的患者。
  • 受试者随机接受标准药物治疗(SMT)或SMT+TEVAR,TEVAR须在症状发作后2-12周内进行。
  • 试验注册号ClinicalTrials.gov NCT05215587,注册日期2022年1月31日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary management of uncomplicated type B aortic dissections (uTBAD) is based on the acuity and various morphological features. Medical therapy is mandatory, while the risks of early thoracic endovascular aortic repair (TEVAR) are balanced against the potential for rupture, complex surgery, and death. Improved aortic morphology following TEVAR is documented, but evidence for improved overall survival is lacking. The costs and impact on quality of life are also needed. METHODS: The trial is a randomized, open-label, superiority clinical trial with parallel assignment of subjects at 23 clinical sites in Denmark, Norway, Sweden, Finland, and Iceland. Eligibility includes patients aged ≥ 18 with uTBAD of < 4 weeks duration. Recruited subjects will be randomized to either standard medical therapy (SMT) or SMT + TEVAR, where TEVAR must be performed between 2-12 weeks from the onset of symptoms. DISCUSSION: This trial will evaluate the primary question of whether early TEVAR improves survival at 5 years among uTBAD patients. Moreover, the costs and the impact on quality of life should provide sorely needed data on other factors that play a role in treatment strategy decisions. The common Nordic healthcare model, with inclusion of all aortic centers, provides a favorable setting for carrying out this trial, while the robust healthcare registries ensure data validity. TRIAL REGISTRATION: ClinicalTrials.gov NCT05215587. Registered on January 31, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rudolph C, Lindberg BR, Resch T, et al. Scandinavian trial of uncomplicated aortic dissection therapy: study protocol for a randomized controlled trial. Trials. 2023. PMID: 36949478. doi:10.1186/s13063-023-07255-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。